Regulatory drug rollout

Nigeria Rolls Out Lenacapavir for HIV Prevention

Analysis based on 40 articles · First reported Mar 11, 2026 · Last updated Mar 12, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The rollout of Lenacapavir in Nigeria is a positive development for the pharmaceutical and healthcare sectors, particularly for companies involved in HIV prevention and treatment. It signifies a growing market for long-acting PrEP drugs and could encourage further investment in similar innovations.

Pharmaceuticals Healthcare

Event Summary

Nigeria has commenced the rollout of Lenacapavir, a long-acting injectable drug for the prevention of HIV infection. This initiative, led by the Nigeria===Federal Ministry of Health and Social Welfare, aims to eradicate HIV/AIDS as a public health threat by 2030. The drug, administered biannually, offers high efficacy and improved adherence, particularly for vulnerable populations. The rollout will begin on a controlled scale in eight states and the Federal Capital Territory, with plans for nationwide expansion. This move complements existing prevention methods like oral PrEP and is considered a major milestone in Nigeria's HIV prevention response. Officials like Iziaq Adekunle Salako and Temitope Ilori have emphasized the drug's benefits while also noting its limitations, such as not being recommended for pregnant women and not protecting against other STIs.

Key Actions

100 Nigeria received Long-Acting Injectable Lenacapavir for HIV prevention

100 Nigeria rolled out long-acting injectable drug for HIV prevention

90 Nigeria===National AIDS, Viral Hepatitis and STIs Control Programme announced arrival and strategic deployment of Lenacapavir

90 Nigeria===Federal Ministry of Health and Social Welfare announced rollout of Lenacapavir

80 Nigeria===Federal Ministry of Health and Social Welfare confirmed arrival of Lenacapavir

80 Iziaq Adekunle Salako stated government's commitment to ending HIV/AIDS

60 Gilead Sciences developed Lenacapavir

60 Nigeria===National Agency for the Control of AIDS provided information on Lenacapavir's usage

+ 2 more actions View on Dashboard

Entities Involved

cnt

Nigeria

Nigeria has commenced the rollout of Lenacapavir, a long-acting injectable drug for HIV prevention, aiming to eradicate HIV/AIDS as a public health threat by 2030. This initiative is expected to accelerate the reduction of new HIV infections and strengthen the country's prevention efforts.

Importance 100 Sentiment 30

govactor

Nigeria===Federal Ministry of Health and Social Welfare

The Nigeria===Federal Ministry of Health and Social Welfare is leading the rollout of Lenacapavir in Nigeria, demonstrating its commitment to ending HIV/AIDS. The ministry is overseeing the controlled introduction and future expansion of the drug.

Importance 90 Sentiment 20

per

Iziaq Adekunle Salako

Iziaq Adekunle Salako, Minister of State for Health and Social Welfare, announced the rollout of Lenacapavir, highlighting the government's commitment to HIV prevention and control. He emphasized the drug's efficacy and the phased implementation plan.

Importance 80 Sentiment 20

govactor

Nigeria===National AIDS, Viral Hepatitis and STIs Control Programme

The Nigeria===National AIDS, Viral Hepatitis and STIs Control Programme (NASCP) is involved in the media parley and the implementation of the Lenacapavir rollout. Its national coordinator, Adebobola Bashorun, discussed plans for expanding access to the drug.

Importance 70 Sentiment 20

per

Adebobola Bashorun

Adebobola Bashorun, the national coordinator of NASCP, confirmed the federal government's efforts to expand access to Lenacapavir across more states. He noted that the new injectable option complements existing HIV prevention methods.

Importance 60 Sentiment 15

govactor

Nigeria===National Agency for the Control of AIDS

The Nigeria===National Agency for the Control of AIDS (NACA) director-general, Temitope Ilori, provided important information regarding Lenacapavir, including its non-recommendation for pregnant women and its lack of protection against other STIs.

Importance 60 Sentiment 15

stock

Gilead Sciences

Gilead Sciences developed Lenacapavir, the long-acting injectable drug for HIV prevention, which has now been introduced in Nigeria.

Importance 60 Sentiment 30

+ 5 more entities View on Dashboard

Relationships

Iziaq Adekunle Salako related ↔ Nigeria===Federal Ministry of Health and Social Welfare

Adebobola Bashorun related ↔ Nigeria===National AIDS, Viral Hepatitis and STIs Control Programme

Temitope Ilori related ↔ Nigeria===National Agency for the Control of AIDS

Nigeria related ↔ Nigeria===Federal Ministry of Health and Social Welfare

Nigeria===National AIDS, Viral Hepatitis and STIs Control Programme related ↔ Nigeria===Federal Ministry of Health and Social Welfare

Nigeria related ↔ Nigeria===National Agency for the Control of AIDS

Iziaq Adekunle Salako related ↔ Nigeria

Nigeria related ↔ Nigeria===National AIDS, Viral Hepatitis and STIs Control Programme

Iziaq Adekunle Salako related ↔ Nigeria===National AIDS, Viral Hepatitis and STIs Control Programme

Muhammad Ali Pate related ↔ Nigeria===Federal Ministry of Health and Social Welfare

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard